Mackenzie Financial Corp Cyma Bay Therapeutics, Inc. Transaction History

Mackenzie Financial Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$7.47 - $10.95 $108,449 - $158,972	-14,518 Reduced 28.93%	35,660 $390,000
Q1 2023 Apr 24, 2023	BUY	$5.88 - $9.59 $295,046 - $481,207	50,178 New	50,178 $437,000
Q4 2020 Feb 10, 2021	SELL	$5.73 - $9.03 $694,476 - $1.09 Million	-121,200 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$3.32 - $7.24 $402,384 - $877,488	121,200 New	121,200 $877,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.